TY - JOUR
T1 - Drug-resistant tuberculosis treatment success predictors in Namibia
AU - Nangombe, Vulika
AU - Amkongo, Mondjila
AU - Godman, Brian
AU - Kibuule, Dan
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - Background: Drug-resistant tuberculosis (DR-TB) is a considerable barrier to ending TB globally by 2035. In most high TB-burden countries in the sub-Saharan region, drivers of DR-TB treatment success are unknown. Objectives: To determine predictors and patterns of treatment success rates (TSRs) in DR-TB in Namibia to inform strategies of national TB programmes. Methods: A nationwide retrospective observational cohort study of a 6 year DR-TB database, 2014–19, was carried out. Independent predictors of successful treatment outcome in DR-TB were determined by multivariate logistic regression. Results: Of the 1494 DR-TB patients included, 56.3% (n=841) were male, the mean (±SD) age was 35.6± 14.2 years, and 8.3% had TB/HIV coinfection. The overall TSR was 66.5% (n=994) and it increased marginally between implementation of the second and third medium-term plans for TB and leprosy (MTP-II and MTP-III). Being female was associated with lower odds of treatment success [adjusted OR (aOR)=0.6; 95% CI: 0.34–0.89; P=0.015), as was a young age (under 5 years) (aOR=0.1; 95% CI: 0.0007–0.421; P=0.005) and ages of 5–14 years (aOR=0.0; 95% CI: 0.002–0.269; P=0.002). Namibian nationality also showed a reduced likelihood of treatment success (aOR=0.3; 95% CI: 0.089–0.961; P=0.043). Among clinical predictors, bilateral pulmonary forms were inversely associated with treatment success (aOR=0.2; 95% CI: 0.057–0.498; P=0.001). Conversely, baseline monoresistance was linked to an increased likelihood of treatment success (aOR=7.6; 95% CI: 1.427–40.631; P=0.018). Conclusions: Whilst DR-TB TSRs improved, they are below the global target and vary by clinical and patient demographics. Targeted interventions for high-risk patients, including female patients, those aged under 15 years, locals and those with bilateral pulmonary disease using community-based approaches to boost adherence, alongside leveraging the skills of clinical pharmacists, should now be explored.
AB - Background: Drug-resistant tuberculosis (DR-TB) is a considerable barrier to ending TB globally by 2035. In most high TB-burden countries in the sub-Saharan region, drivers of DR-TB treatment success are unknown. Objectives: To determine predictors and patterns of treatment success rates (TSRs) in DR-TB in Namibia to inform strategies of national TB programmes. Methods: A nationwide retrospective observational cohort study of a 6 year DR-TB database, 2014–19, was carried out. Independent predictors of successful treatment outcome in DR-TB were determined by multivariate logistic regression. Results: Of the 1494 DR-TB patients included, 56.3% (n=841) were male, the mean (±SD) age was 35.6± 14.2 years, and 8.3% had TB/HIV coinfection. The overall TSR was 66.5% (n=994) and it increased marginally between implementation of the second and third medium-term plans for TB and leprosy (MTP-II and MTP-III). Being female was associated with lower odds of treatment success [adjusted OR (aOR)=0.6; 95% CI: 0.34–0.89; P=0.015), as was a young age (under 5 years) (aOR=0.1; 95% CI: 0.0007–0.421; P=0.005) and ages of 5–14 years (aOR=0.0; 95% CI: 0.002–0.269; P=0.002). Namibian nationality also showed a reduced likelihood of treatment success (aOR=0.3; 95% CI: 0.089–0.961; P=0.043). Among clinical predictors, bilateral pulmonary forms were inversely associated with treatment success (aOR=0.2; 95% CI: 0.057–0.498; P=0.001). Conversely, baseline monoresistance was linked to an increased likelihood of treatment success (aOR=7.6; 95% CI: 1.427–40.631; P=0.018). Conclusions: Whilst DR-TB TSRs improved, they are below the global target and vary by clinical and patient demographics. Targeted interventions for high-risk patients, including female patients, those aged under 15 years, locals and those with bilateral pulmonary disease using community-based approaches to boost adherence, alongside leveraging the skills of clinical pharmacists, should now be explored.
UR - http://www.scopus.com/inward/record.url?scp=85213016552&partnerID=8YFLogxK
U2 - 10.1093/jacamr/dlae211
DO - 10.1093/jacamr/dlae211
M3 - Article
AN - SCOPUS:85213016552
SN - 2632-1823
VL - 6
JO - JAC-Antimicrobial Resistance
JF - JAC-Antimicrobial Resistance
IS - 6
M1 - dlae211
ER -